These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3277664)

  • 1. A double-crossover trial comparing the effects of topical carteolol and placebo on intraocular pressure.
    Duff GR; Graham PA
    Br J Ophthalmol; 1988 Jan; 72(1):27-8. PubMed ID: 3277664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 12-hour control of intraocular pressure on carteolol 2% twice daily.
    Duff GR; Newcombe RG
    Br J Ophthalmol; 1988 Dec; 72(12):890-1. PubMed ID: 3067744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-masked comparison of carteolol and timolol in ocular hypertension.
    Scoville B; Mueller B; White BG; Krieglstein GK
    Am J Ophthalmol; 1988 Feb; 105(2):150-4. PubMed ID: 3277436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure.
    Duff GR
    Acta Ophthalmol (Copenh); 1987 Oct; 65(5):618-21. PubMed ID: 3321878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the ocular hypotensive efficacy and systemic safety of 0.5% levobunolol and 2% carteolol.
    Behrens-Baumann W; Kimmich F; Walt JG; Lue J
    Ophthalmologica; 1994; 208(1):32-6. PubMed ID: 8145982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tolerance and pharmacologic effectiveness of antiglaucoma eyedrops].
    Flury H; Tournoux A; Martenet AC
    Klin Monbl Augenheilkd; 1986 Jun; 188(6):573-5. PubMed ID: 3761959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Carteolol: general practice-oriented assessment of the effectiveness and tolerance of a new beta-blocker in the treatment of glaucoma].
    Schnaudigel OE; Becker H; Fuchs HB
    Klin Monbl Augenheilkd; 1988 Mar; 192(3):248-51. PubMed ID: 3374015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carteolol: preliminary study on ocular pressure-reducing action.
    Gorgone G; Spina F; Amantia L
    Ophthalmologica; 1983; 187(3):171-3. PubMed ID: 6355953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aqueous humor flow measured by fluorophotometry. A comparative study of the effect of various beta-blocker eyedrops in patients with ocular hypertension].
    Coulangeon LM; Sole M; Menerath JM; Sole P
    Ophtalmologie; 1990; 4(2):156-61. PubMed ID: 2235007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ocular hypotensive effects of carteolol hydrochloride in primary open-angle glaucoma and ocular hypertensive patients. A double-masked cross-over study for the determination of concentrations optimal for the clinical use (author's transl)].
    Kitazawa Y; Azuma I; Takase M; Komemushi S
    Nippon Ganka Gakkai Zasshi; 1981; 85(7):798-804. PubMed ID: 7030018
    [No Abstract]   [Full Text] [Related]  

  • 12. [Ocular hypotensive effect of 1% carteolol long-acting eye drops--a double-masked, randomized phase III study in ocular hypertension or primary open-angle glaucoma patients comparing long-acting carteolol eye drops vs. current product].
    Yamamoto T;
    Nippon Ganka Gakkai Zasshi; 2007 Jun; 111(6):463-72. PubMed ID: 17601060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of 0.004% travoprost and 2% carteolol on intraocular pressure in patients with ocular hypertension after laser peripheral iridotomy or trabeculectomy in primary angle-closure glaucoma].
    Yao BQ; Pang YY; Li YX
    Zhonghua Yan Ke Za Zhi; 2013 Apr; 49(4):340-4. PubMed ID: 23900094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of beta-blocking agent carteolol on healthy volunteers and glaucoma patients (author's transl)].
    Negishi C; Ueda S; Kanai A; Nakajima A; Funahashi M; Kitazawa Y; Komemushi S
    Nippon Ganka Gakkai Zasshi; 1981 Jan; 85(1):57-66. PubMed ID: 6114632
    [No Abstract]   [Full Text] [Related]  

  • 15. Antihypertensive effect of carteolol in thiazide-treated hypertensive subjects.
    Velasquez MT; Byrne D; Hoffmann RG
    J Clin Pharmacol; 1985; 25(8):601-6. PubMed ID: 3908501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and tolerability of 2 presentations of eyedrops combining carteolol 2% and pilocarpine 2% in primary open-angle glaucoma and simple ocular hypertension].
    Sirbat D; Charlin JF; Cohn H; Dascotte JC; George JL; Lesure P; Massin M; Massin G; Maurin JF; Renard JP
    J Fr Ophtalmol; 1995; 18(10):589-96. PubMed ID: 8568162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical experiences with carteolol in patients with essential hypertension].
    Viehmann P
    Arzneimittelforschung; 1983; 33(2a):322-5. PubMed ID: 6340701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypotensive effect of carteolol on intraocular pressure elevation and secondary glaucoma associated with endogenous uveitis.
    Ohno S; Ichiishi A; Matsuda H
    Ophthalmologica; 1989; 199(1):41-5. PubMed ID: 2761985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypotensive action of 0.5% carteolol versus 0.1% timolol in patients with intraocular hypertension].
    Allaire C; Trinquand C; Nordmann JP; Dascotte JC; George JL; Lesure P; Rouland JF; Khaitrine L; Sirbat D
    J Fr Ophtalmol; 1995; 18(1):22-6. PubMed ID: 7738291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remission of mild to moderate hypertension after treatment with carteolol, a beta-adrenoceptor blocker with intrinsic sympathomimetic activity.
    Giles TD; Sander GE; Roffidal L; Thomas MG; Mersch DP; Moyer RR; Burris JF; Mroczek WJ; Brachfeld J
    Arch Intern Med; 1988 Aug; 148(8):1725-8. PubMed ID: 3041936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.